Paion AG (0NF3.L)
0NF3.L Stock Price Chart
Explore Paion AG interactive price chart. Choose custom timeframes to analyze 0NF3.L price movements and trends.
0NF3.L Company Profile
Discover essential business fundamentals and corporate details for Paion AG (0NF3.L) to support your stock research and investment decisions.
Sector
Healthcare
Industry
Medical - Pharmaceuticals
IPO Date
10 Mar 2023
Employees
64.00
Website
https://www.paion.comCEO
Gregor Siebert
Description
Paion AG, a specialty pharmaceutical company, develops and commercializes drugs for hospital-based sedation, anesthesia, and critical care services worldwide. The company's lead product is Remimazolam, an ultra-short-acting intravenous benzodiazepine sedative/anesthetic, which is in clinical development for use in procedural sedation, general anesthesia, and intensive care unit sedation. It is also developing Angiotensin II, a vasoconstrictor indicated for the treatment of refractory hypotension in adults with septic or other distributive shock; and Eravacycline, a novel fluorocycline antibiotic indicated for the treatment of complicated intra-abdominal infections in adults. The company has partnerships and license agreements with Cosmo Pharmaceuticals, Wuhan Humanwell Innovative Drug Research and Development Center Limited Company, Hana Pharm, Yichang Humanwell, and Mundipharma. Paion AG was founded in 2000 and is based in Aachen, Germany.
0NF3.L Financial Timeline
Browse a chronological timeline of Paion AG corporate events including earnings releases, dividend announcements, and stock splits.
Earnings released on 2 Jun 2025
Earnings released on 28 Mar 2025
Earnings released on 4 Nov 2024
Earnings released on 24 Sept 2024
Earnings released on 15 May 2024
Earnings released on 28 Mar 2024
Earnings released on 30 Jun 2023
EPS came in at -€1.35, while revenue for the quarter reached €6.79M.
Stock split effective on 18 May 2023
Shares were split 1:10, changing the number of shares outstanding and the price per share accordingly.
Stock split effective on 12 Apr 2023
Shares were split 1:10, changing the number of shares outstanding and the price per share accordingly.
Earnings released on 31 Mar 2023
EPS came in at -€0.68, while revenue for the quarter reached €3.40M.
Earnings released on 31 Dec 2022
EPS came in at -€1.44, while revenue for the quarter reached €8.02M.
Earnings released on 30 Sept 2022
EPS came in at -€1.05, while revenue for the quarter reached €371.00K.
Earnings released on 30 Jun 2022
EPS came in at €1.35, while revenue for the quarter reached €25.23M.
Earnings released on 31 Mar 2022
EPS came in at €0.68, while revenue for the quarter reached €12.62M.
Dividend declared on 15 Mar 2022
A dividend of €0.00 per share was announced, adjusted to €0.29.
Earnings released on 31 Dec 2021
EPS came in at -€1.59, while revenue for the quarter reached €3.51M.
Earnings released on 30 Sept 2021
EPS came in at -€0.90, while revenue for the quarter reached €1.88M.
Earnings released on 30 Jun 2021
EPS came in at -€1.50, while revenue for the quarter reached €3.62M.
Earnings released on 31 Mar 2021
EPS came in at -€0.75, while revenue for the quarter reached €1.81M.
Stock split effective on 24 Mar 2021
Shares were split 1017:1000, changing the number of shares outstanding and the price per share accordingly.
Earnings released on 31 Dec 2020
EPS came in at €1.23, while revenue for the quarter reached €16.14M.
Earnings released on 30 Sept 2020
EPS came in at €1.80, while revenue for the quarter reached €15.75M.
0NF3.L Stock Performance
Access detailed 0NF3.L performance analysis with candlestick charts, real‑time intraday data and historical financial metrics for comprehensive insights.
Explore Related Stocks
Compare companies within the same sector by viewing performance, key financials, and market trends. Select a symbol to access the full profile.